Contrive Datum Insights has published "Organ On Chips Market Size, Share & Industry Analysis, By Product type (Instruments & Devices, Consumables (Chips & Reagents), Software & Services), Organ model (Liver-on-Chip, Lung-on-Chip, Kidney-on-Chip, Heart-on-Chip, Multi-Organ / Other Models), Application (Drug Discovery & Development, Toxicology & Safety Testing, Disease Modeling, Personalized Medicine & Other Applications), End user (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Government Research Institutes, Cosmetics & Other Industries), Technology (Single-Organ-on-Chip Systems, Multi-Organ (Body-on-Chip) Systems), and Regional Forecast, 2026-2034". The study sizes the global organ on chips market at USD 105 million in 2025 and projects growth from USD 132 million in 2026 to USD 718 million by 2034, a compound annual growth rate of 23.57% across the forecast period.
Organ-on-chip systems are microfluidic devices that recreate the structure and function of a specific human tissue or organ on a small chip, used to observe how living cells respond to a drug, chemical or disease condition under controlled flow and mechanical conditions. Buyers are primarily pharmaceutical and biotechnology researchers evaluating drug candidates before animal or clinical testing, alongside contract research organizations, academic laboratories and, increasingly, cosmetics and chemical safety testing groups seeking an alternative to animal-based methods. The category spans standalone chip devices, the instruments that operate them, and the software used to capture and interpret the resulting data.
Regulatory shift away from mandatory animal testing (FDA Modernization Act 2.0 and comparable reforms)
Regulatory shift away from mandatory animal testing (FDA Modernization Act 2.0 and comparable reforms) is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 23.57% a year, the product type lines exposed to it move fastest: Software & Services compounds at 26.34%, taking its share of revenue from 18% to 22% and its value from USD 18.9 million to USD 157.96 million.
A more favourable outcome is possible. If regulatory agencies fast-track acceptance of organ-chip data across more indications, moving pharmaceutical sponsors away from animal protocols faster than current guidance implies, 2034 revenue reaches USD 811 million instead of the USD 718 million the base case carries.
On the downside, regulatory acceptance of chip-based data advances more slowly than current guidance implies, keeping animal protocols as the default for a larger share of drug-safety studies through the forecast period, which would hold 2034 revenue to USD 617 million. Instruments & Devices, which carries 34% of 2025 revenue, already grows at only 20.91% against the market's 23.57%, so the largest part of the base is also its slowest.
Where the Competition Actually Sits
Competition in the global organ on chips market runs along the product type axis, not the regional one. Consumables (Chips & Reagents) holds 48% of 2025 revenue at USD 50.4 million and remains the largest line through 2034 at 50%, making it the position hardest for a challenger to take. Software & Services, growing at 26.34%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 105 million.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Organ model | Liver-on-Chip | 30% · USD 31.5 million | Multi-Organ / Other Models 26.36% |
| Application | Drug Discovery & Development | 45% · USD 47.25 million | Personalized Medicine & Other Applications 28.54% |
| End user | Pharmaceutical & Biotechnology Companies | 52% · USD 54.6 million | Cosmetics & Other Industries 30.45% |
| Technology | Single-Organ-on-Chip Systems | 68% · USD 71.4 million | Multi-Organ (Body-on-Chip) Systems 27.62% |
- North America was the largest region in 2025, holding 42% of global revenue at USD 44.1 million and reaching USD 272.84 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 21% in 2025 to 27% in 2034, with revenue growing from USD 22.05 million to USD 193.86 million.
- Middle East and Africa remains the smallest region throughout, at 3% of 2025 revenue and 3% by 2034.
- By product type, the largest line in 2025 was Consumables (Chips & Reagents), at 48% of revenue and USD 50.4 million.
- No product type line grows faster than Software & Services, at a projected 26.34%.
- The United States is the largest single country market at USD 39.69 million in 2025, 37.8% of global revenue.
The study covers five axes, by product type, and by organ model, application, end user and technology, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 617 million and USD 811 million by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.